News
January 18, 2024
TScan Therapeutics Announces Best Abstracts Award and Upcoming Oral Presentation at the 2024 Tandem Meetings of ASTCT and CIBMTR
January 4, 2024
TScan Therapeutics Announces 2024 Clinical Plans and Highlights Recent Progress
December 9, 2023
TScan Therapeutics Presents Initial Phase 1 Clinical Results on TSC-100 and TSC-101 at the 65th American Society of Hematology Annual Meeting and Exposition
December 7, 2023
TScan Therapeutics Appoints R. Keith Woods to its Board of Directors, Bringing Expertise in Commercialization and Global Operations
December 4, 2023
TScan Therapeutics to Host Virtual KOL Event to Discuss Results from Ongoing Phase 1 Trial of TSC-100 and TSC-101 Presented at the 65th ASH Annual Meeting and Exposition
December 4, 2023
TScan Therapeutics Expands Manufacturing Leadership with the Appointment of Justin McCue, Ph.D., as Chief Technology Officer
November 30, 2023
TScan Therapeutics Named Top Place to Work by The Boston Globe for Two Consecutive Years
November 9, 2023
TScan Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
November 6, 2023
TScan Therapeutics Presents Phase 1 Trial Design for Solid Tumor Program at the Society for Immunotherapy of Cancer 38th Annual Meeting
November 2, 2023